Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

被引：0

作者：

Gumuzio, Juan

Calleja, Veronique

Miles, James

Sancehz-Magraner, Lissete

Aguirre, Fernando

机构：

来源：

MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期

关键词：

D O I：

10.1158/1535-7163.TARG-23-A124

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A124

引用

页数：2

共 50 条

[31] A snapshot of the PD-1/PD-L1 pathway
Ghosh, Chinmoy
Luong, Gary
Sun, Yue
JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
[32] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
Barclay, Jonathan
Creswell, Joanne
Leon, Juan
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
[33] PD-1 and PD-L1 antibodies for melanoma
Tsai, Katy K.
Zarzoso, Ines
Daud, Adil I.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (11) : 3111 - 3116
[34] PD-1/PD-L1 in cardiovascular disease
Sun, YunFeng
Li, Liang
Wu, YaWei
Yang, KePing
CLINICA CHIMICA ACTA, 2020, 505 : 26 - 30
[35] Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor
Oh, Wonkyung
Kim, Alyssa Min Jung
Dhawan, Deepika
Knapp, Deborah W.
Lim, Seung-Oe
MOLECULAR THERAPY, 2025, 33 (02)
[36] Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Zitvogel, Laurence
Kroemer, Guido
ONCOIMMUNOLOGY, 2012, 1 (08): : 1223 - 1225
[37] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares
Claire Battin
Sabrina Jutz
Judith Leitner
Christine Hafner
Joshua Tobias
Ursula Wiedermann
Michael Kundi
Gerhard J. Zlabinger
Katharina Grabmeier-Pfistershammer
Peter Steinberger
Scientific Reports, 9
[38] PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B Paiva
A Azpilikueta
N Puig
E M Ocio
R Sharma
B O Oyajobi
S Labiano
L San-Segundo
A Rodriguez
I Aires-Mejia
I Rodriguez
F Escalante
A G de Coca
A Barez
J F San Miguel
I Melero
Leukemia, 2015, 29 : 2110 - 2113
[39] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Linhares, Annika De Sousa
Battin, Claire
Jutz, Sabrina
Leitner, Judith
Hafner, Christine
Tobias, Joshua
Wiedermann, Ursula
Kundi, Michael
Zlabinger, Gerhard J.
Grabmeier-Pfistershammer, Katharina
Steinberger, Peter
SCIENTIFIC REPORTS, 2019, 9 (1)
[40] PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Paiva, B.
Azpilikueta, A.
Puig, N.
Ocio, E. M.
Sharma, R.
Oyajobi, B. O.
Labiano, S.
San-Segundo, L.
Rodriguez, A.
Aires-Mejia, I.
Rodriguez, I.
Escalante, F.
de Coca, A. G.
Barez, A.
San Miguel, J. F.
Melero, I.
LEUKEMIA, 2015, 29 (10) : 2110 - 2113

← 1 2 3 4 5 →

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (&lt;1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment

Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment